TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04128878

Intervention type: DRUG
Intervention: Sotalol
Description: The primary goal of the study will be to evaluate the change in endothelial function seen after initiating anti-arrhythmic medical therapy. Testing will be performed at baseline prior to the 1st dose of anti-arrhythmic therapy and again 1-3 months later at outpatient follow-up visit. We will record the resting flow (RF), biological zero (BZ) and peak flow (PF) as perfusion units (PU). Specifically, we will assess arterial stiffness and vasodilation in response to acetylcholine iontophoresis, nitroprusside iontophoresis, local thermal hyperemia and reactive hyperemia. Laser speckle contrast imaging will be employed to evaluate the microvasculature. SphygmoCor (arterial tonometry) will be used to assess macrovasculature.
Study: NCT02152995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT04128878

Intervention type: DRUG
Intervention: Dofetilide
Description: Same as described above with sotalol.
Study: NCT01255579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol Fluticasone
Description: salmeterol 50 mcg and fluticasone 250 mcg (diskus) b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol - beclometasone
Description: formoterol 12 mcg and beclometasone 200 mcg HFA (by MDI) b.i.d.
Study: NCT02261675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: children received intravenous infusion with a bolus dose dexmedetomidine and followed by a continuous infusion before induction. use sevoflurane for induction and a steady-state end-tidal sevoflurane concentration was maintained for at least 15 min before skin incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: children received intravenous infusion with a bolus dose dexmedetomidine and followed by a continuous infusion before induction. use sevoflurane for induction and a steady-state end-tidal sevoflurane concentration was maintained for at least 15 min before skin incision.
Study: NCT00795977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cells, OK-432
Description: Single Group Assignment
Study: NCT02948205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D group
Description: infertility patient get TU-LESS by 3D Laparoscopy
Study: NCT02572973

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic Neuromodulation (ANM)
Description: The purpose of this study is test the safety of the Acoustic Neuromodulation (ANM) treatment and see what effects it has on your child's anxiety symptoms. Observation and anecdotal evidence suggest that this is an effective intervention for anxiety disorders. This is the first research study to test this theory, and could lead to more robust studies in the future. This study intends to assess the efficacy of this type of intervention for children with an anxiety disorder. As this is only a pilot study, the results will also inform the design and execution of future research on this treatment. We hope to add to the growing literature supporting novel treatment approaches for affected individuals.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acoustic Neuromodulation (ANM)
Description: The purpose of this study is test the safety of the Acoustic Neuromodulation (ANM) treatment and see what effects it has on your child's anxiety symptoms. Observation and anecdotal evidence suggest that this is an effective intervention for anxiety disorders. This is the first research study to test this theory, and could lead to more robust studies in the future. This study intends to assess the efficacy of this type of intervention for children with an anxiety disorder. As this is only a pilot study, the results will also inform the design and execution of future research on this treatment. We hope to add to the growing literature supporting novel treatment approaches for affected individuals.
Study: NCT03523507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active: rTMS
Description: Daily sessions will consist of 3000 left-sided excitatory pulses at 10 Hz (with 4-second trains and 26-second inter-train interval) followed by 1000 right-sided inhibitory pulses at 1 Hz (in a single train). The DLPFC treatment target will be determined using individualized resting-state network mapping.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham: rTMS
Description: Daily sessions will consist of the same total number of sham pulses, designed to have similar sound and tactile sensation, without producing active stimulation.
Study: NCT00360282

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: In an unlabeled pill given once on one of two visits.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: In an unlabeled pill given once on one of two visits.
Study: NCT02576574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants received Cisplatin 75 mg/m\^2 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 6 mg/mL\*min by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with pemetrexed, or paclitaxel until disease progression or unacceptable toxicities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Weekly
Description: Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks.
Study: NCT00870805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral ultrabrief ECT
Description: Bilateral ECT at 3-4 times seizure threshold with an ultrabrief pulse (0.3ms)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral standard ECT
Description: Bilateral ECT with at 1.5 times seizure threshold with a standard pulse (1.0ms)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: right-unilateral ultrabrief ECT
Description: Right-unilateral ECT at 6 times seizure threshold with an ultrabrief pulse (0.3ms)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: right-unilateral standard ECT
Description: Right-unilateral ECT with at 5 times seizure threshold with a standard pulse (1.0ms)
Study: NCT00968396

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Co-culture Stem Cell Infusion on Day 0.
Study: NCT00547391

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy
Description: Tonsillectomy under general anesthesia as a day surgery using diathermy or blunt dissection. Follow up started from the day of surgery.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: no intervention
Description: No intervention (controls). Follow up started from the day of randomization.
Study: NCT00968396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 100 mg/m\^2 IV over 30 minutes daily on Days -2 and -1
Study: NCT04610073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive multimedia training and illustrated booklet
Description: The experimental groups conducted interactive multimedia training and illustrated booklet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive multimedia training and illustrated booklet
Description: The experimental groups conducted interactive multimedia training and illustrated booklet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive multimedia training and illustrated booklet
Description: The experimental groups conducted interactive multimedia training and illustrated booklet
Study: NCT01217528

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: device settings for group A
Description: VT zone: 350ms VF zone: 280ms

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device settings for group B
Description: VT zone: 320ms VF zone: 250ms
Study: NCT04098068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: MK-3475 (pembrolizumab) 200 mg flat dose every 21 days
Study: NCT04401579

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The matching Baricitinib placebo contains lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The coating for the placebo tablet is identical to that of the corresponding active tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
Study: NCT01917188

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Full simulation and education

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: See simulation room, usual education
Study: NCT00580333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Preoperatively: Given intravenously on day one of the treatment cycle (once every 3 weeks) for four cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Preoperatively: Given intravenously on day 1 of the treatment cycle (once every three weeks) for three cycles Postoperatively: Intravenously for four 2-week cycles (once every two weeks) and after the 8 weeks (study doctor will determine course of treatment) for an additional four 2-week cycles with or with out paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Postoperative: Given intravenously for four 2-week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Postoperative: Given intravenously for four two-week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Postoperative: 8 weeks after postoperative chemotherapy regimen (study doctor will determine course of treatment) paclitaxel for four 2-week cycles (once every two weeks)
Study: NCT00975273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capnometry Assisted Respiration Training
Description: Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly, and shallowly in order to raise their PCO2 levels with the assistance of a biofeedback device.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing Awareness
Description: Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly using a biofeedback device.
Study: NCT01745484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPECT-based treatment plan
Description: SPECT will be performed on all patients at baseline. Two treatment plans will be made- functional SPECT-based plan and conventional CT-based plan. Randomization will take place if both plans are satisfying established criteria for tumour coverage and normal tissue sparing. Randomization between Arm 1 and Arm 2 will be done, where the patients will be treated either by SPECT-plan or by CT-plan respectively.~The SPECT data are viewed as a multicoloured image in the spectrum colour setting to allow accurate volume contouring around a predefined colour. The threshold level is adjusted individually for each patient in order to match the size of the SPECT image within the lung volumes defined on CT. A new contour of functional lung is created from the SPECT images using a threshold of 30% of the maximum uptake for each patient. A treatment plan is generated. The principal objective for each plan is to minimize the volume of lungirradiated
Study: NCT03373409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol DPI 90mcg
Description: Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90mcg will be given on one of the 3 treatment days. One inhalation from the DPI will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol DPI 180mcg
Description: Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the DPI will be used to deliver the 180mcg dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol HFA MDI
Description: Albuterol HFA MDI delivers 90mcg of albuterol with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the MDI will be used to deliver the 180mcg dose
Study: NCT02845102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-Post Feasibility
Description: The feasibility testing phase will include 25 subjects. Total duration of pre-post feasibility testing will be 6 weeks upon retrieval of the RA-CBT tablet and follow up questionnaires, quantitative exit interview, and/or an optional extended qualitative exit interview. The extended exit interview is a qualitative semi-formal interview focusing on gathering participant experiences working with the intervention, the barriers and facilitators encountered, as well as overall feedback for the pre-post feasibility study and the relational agent.
Study: NCT00021229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: * Phase 1 Stratum I: Starting dose level of 350 mg/m2/day every 28 days X 13 courses (dose escalation)~* Phase I Stratum IIA: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~* Phase I Stratum IIB: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~* Phase II: Phase I Stratum I determined dose (Maximum tolerated dose) every 28 days X 13 courses.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: local irradiation therapy
Description: * Phase I Stratum I: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib.~* Phase II: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib.
Study: NCT00732342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Prizes given for targeted behavior of abstinence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Prizes given for targeted behavior of abstinence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Prizes given for targeted behavior of abstinence
Study: NCT04209218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted blood pressure management
Description: Blood pressure is maintained within ±10% from baseline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted blood pressure management
Description: Blood pressure is maintained within ±10% from baseline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (2 ml normal saline) is administered before anesthesia induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (2 ml normal saline) is administered before anesthesia induction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine blood presure management
Description: Blood pressure is maintained according to routine practice.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine blood presure management
Description: Blood pressure is maintained according to routine practice.
Study: NCT04397250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: Arm-cranking exercise
Study: NCT02268188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: Attend classes as part of Harvesting Health program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition intervention
Description: Learn how to incorporate nutrition guidelines into daily meal plans as part of Harvesting Health program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Use FitBit to log daily steps as part of Harvesting Health program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT02964884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovastatin
Description: Those in the Lovastatin group will receive 20mg of Lovastatin per day for the first two weeks and 40mg of Lovastatin per day starting at week 3 through week 11.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: reading tutoring intervention
Description: After the initial 12 weeks of Lovastatin or placebo, children will return for one week of intensive, one-on-one tutoring intervention (either reading or sham; Visit 2)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: reading tutoring intervention
Description: After the initial 12 weeks of Lovastatin or placebo, children will return for one week of intensive, one-on-one tutoring intervention (either reading or sham; Visit 2)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: reading tutoring intervention
Description: After the initial 12 weeks of Lovastatin or placebo, children will return for one week of intensive, one-on-one tutoring intervention (either reading or sham; Visit 2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Those in the placebo group will receive a tablet daily

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Other Academic sham tutoring
Description: No reading (sham) tutoring. Children will receive intensive tutoring on a subject other than reading.
Study: NCT04401579

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name \[1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl\]acetonitrile Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
Study: NCT01987024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actim Partus® test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual procedure
Study: NCT02681107

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: APBI 27Gy in 5 fractions
Description: Patients will be treated with 3-D conformal, external beam, partial breast RT to deliver 27 Gy in 5 daily fractions using 3-5 beams on a linear accelerator. The target PTV will be the CT-visible seroma plus a 1cm margin to form the CTV (minus 5mm from skin and excluding chest wall) and a further 7mm to form the PTV. Real time review will ensure compliance with target and normal tissues dose constraints in this multi-institutional study. Any (or no) systemic therapy is permitted.
Study: NCT01032759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: 20 mg, BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID
Study: NCT02775227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pasireotide
Study: NCT02948205

Intervention type: PROCEDURE
Group type: OTHER
Intervention: normal group
Description: infertility patient get normal laparoscopic surgery
Study: NCT03628612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AUTO CAR T cell therapy
Description: No study drug is administered in this study. Patients previously treated with AUTO CAR T cell therapy will be monitored for safety following the first infusion.
Study: NCT01518517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRASPA
Description: one injection of GRASPA 150 IU/kg at each cycle of chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-asparaginase
Description: 3 to 4 Injections of Native E.coli asparaginase 10000IU/m² (every 3 days) at each cycle of chemotherapy
Study: NCT02672345

Intervention type: DRUG
Intervention: Sevoflurane
Description: The Sevoflurane Group will receive between 0.7 and 1.5% of sevoflurane CAM only during CPB period. While Not Sevoflurane Group will receive only intravenous anesthetic agents.
Study: NCT01754545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octaplas infusion and placebo (group 1)
Description: Intervention period is Monday-Friday in two following weeks. Active treatment with Octaplas is given 2-3 times each week and placebo is given the other 2-3 days of intervention each week. Route of administration is intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octaplas infusion and placebo (group 2)
Description: Intervention period is Monday-Wednesday in two separate weeks (minimum of three weeks between intervention weeks). Active treatment with Octaplas is given once and placebo is given twice each week. Route of administration is intravenously.
Study: NCT01015794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ephedrine hydrochloride
Description: single oral dose, 1mg/kg body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ephedrine hydrochloride
Description: single dose of 1 mg/kg body weight
Study: NCT01849185

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Food supplement